ArticleJournal of Alzheimer's disease reports
The trajectory of delusions in patients with Alzheimer's disease receiving pharmacological treatment: A re-analysis of data from the CATIE-AD trial.
Article in Journal of Alzheimer's disease reports. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies have reported decreases in the proportion of patients with delusions and severity of delusions during long-term follow-up in Alzheimer's disease (AD). Objective: The aim of the present study was to explore clinical predictors of the disappearance of delusions in AD patients enrolled in the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) trial who received pharmacological treatment. Methods: We re-analyzed the data of 421 clinic-based patients enrolled in the CATIE-AD trial to examine the association between the disappearance of delusions and relevant factors selected by reference to previous studies at week 12, 24, and 36 of treatment. Generalized Estimating Equations were used to analyze the impact of the assigned medication (mainly atypical antipsychotics), treatment duration, and their interaction on the disappearance of delusions over time. Results: The proportion of patients with delusions (PWD) gradually decreased to approximately 50% over the 36-week treatment period; however, no significant differences in the baseline variables were identified between the PWD and patients without delusions (POD) at any of the follow-up time-points (weeks 12, 24, or 36). Furthermore, the treatment duration was found to contribute significantly to the disappearance of delusions over time (conversion from PWD at baseline to POD at subsequent follow-up visits), independent of active drug use. Conclusions: Disappearance of delusions in AD patients was associated with the interval from the baseline, regardless of the use of active drugs. Insights into the natural course of delusions could guide clinicians toward selecting alternative treatment strategies for patients with AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.